Review



human rcd5l  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems human rcd5l
    Fig. 4. Recombinant CD5L <t>(rCD5L)</t> suppresses TGFβ-mediated fibrogenic responses in human lung fibroblast cells. Protein levels of COL1A1, FN1, and α-SMA in IMR-90 cells pre-treated with vehicle or rCD5L (0.4 μg/mL) for 3 h, followed by treatment with vehicle or TGFβ (2 ng/mL) for a further 24 h. Representative blots and quantification relative to α-tubulin are shown. Unpaired two-sample Student’s t-test (2-tailed) was used to analyze the difference between rCD5L-treated and vehicle-treated cells, either without or with TGFβ treatment.
    Human Rcd5l, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human rcd5l/product/R&D Systems
    Average 93 stars, based on 5 article reviews
    human rcd5l - by Bioz Stars, 2026-06
    93/100 stars

    Images

    1) Product Images from "CD5L is a target of transcription factor Nrf2."

    Article Title: CD5L is a target of transcription factor Nrf2.

    Journal: Biochemical and biophysical research communications

    doi: 10.1016/j.bbrc.2025.152225

    Fig. 4. Recombinant CD5L (rCD5L) suppresses TGFβ-mediated fibrogenic responses in human lung fibroblast cells. Protein levels of COL1A1, FN1, and α-SMA in IMR-90 cells pre-treated with vehicle or rCD5L (0.4 μg/mL) for 3 h, followed by treatment with vehicle or TGFβ (2 ng/mL) for a further 24 h. Representative blots and quantification relative to α-tubulin are shown. Unpaired two-sample Student’s t-test (2-tailed) was used to analyze the difference between rCD5L-treated and vehicle-treated cells, either without or with TGFβ treatment.
    Figure Legend Snippet: Fig. 4. Recombinant CD5L (rCD5L) suppresses TGFβ-mediated fibrogenic responses in human lung fibroblast cells. Protein levels of COL1A1, FN1, and α-SMA in IMR-90 cells pre-treated with vehicle or rCD5L (0.4 μg/mL) for 3 h, followed by treatment with vehicle or TGFβ (2 ng/mL) for a further 24 h. Representative blots and quantification relative to α-tubulin are shown. Unpaired two-sample Student’s t-test (2-tailed) was used to analyze the difference between rCD5L-treated and vehicle-treated cells, either without or with TGFβ treatment.

    Techniques Used: Recombinant



    Similar Products

    human rcd5l  (R&D Systems)
    93
    R&D Systems human rcd5l
    Fig. 4. Recombinant CD5L <t>(rCD5L)</t> suppresses TGFβ-mediated fibrogenic responses in human lung fibroblast cells. Protein levels of COL1A1, FN1, and α-SMA in IMR-90 cells pre-treated with vehicle or rCD5L (0.4 μg/mL) for 3 h, followed by treatment with vehicle or TGFβ (2 ng/mL) for a further 24 h. Representative blots and quantification relative to α-tubulin are shown. Unpaired two-sample Student’s t-test (2-tailed) was used to analyze the difference between rCD5L-treated and vehicle-treated cells, either without or with TGFβ treatment.
    Human Rcd5l, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human rcd5l/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    human rcd5l - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 4. Recombinant CD5L (rCD5L) suppresses TGFβ-mediated fibrogenic responses in human lung fibroblast cells. Protein levels of COL1A1, FN1, and α-SMA in IMR-90 cells pre-treated with vehicle or rCD5L (0.4 μg/mL) for 3 h, followed by treatment with vehicle or TGFβ (2 ng/mL) for a further 24 h. Representative blots and quantification relative to α-tubulin are shown. Unpaired two-sample Student’s t-test (2-tailed) was used to analyze the difference between rCD5L-treated and vehicle-treated cells, either without or with TGFβ treatment.

    Journal: Biochemical and biophysical research communications

    Article Title: CD5L is a target of transcription factor Nrf2.

    doi: 10.1016/j.bbrc.2025.152225

    Figure Lengend Snippet: Fig. 4. Recombinant CD5L (rCD5L) suppresses TGFβ-mediated fibrogenic responses in human lung fibroblast cells. Protein levels of COL1A1, FN1, and α-SMA in IMR-90 cells pre-treated with vehicle or rCD5L (0.4 μg/mL) for 3 h, followed by treatment with vehicle or TGFβ (2 ng/mL) for a further 24 h. Representative blots and quantification relative to α-tubulin are shown. Unpaired two-sample Student’s t-test (2-tailed) was used to analyze the difference between rCD5L-treated and vehicle-treated cells, either without or with TGFβ treatment.

    Article Snippet: Human rCD5L (2797-CL, R&D Systems) was reconstituted in sterile PBS.

    Techniques: Recombinant